Martingale Asset Management L P purchased a new position in Mesa Laboratories, Inc. (NASDAQ:MLAB) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 8,101 shares of the medical instruments supplier’s stock, valued at approximately $1,161,000. Martingale Asset Management L P owned 0.22% of Mesa Laboratories as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Strs Ohio boosted its holdings in shares of Mesa Laboratories by 5.6% in the second quarter. Strs Ohio now owns 1,900 shares of the medical instruments supplier’s stock worth $272,000 after buying an additional 100 shares during the last quarter. Spark Investment Management LLC purchased a new position in shares of Mesa Laboratories in the second quarter worth approximately $300,000. Alliancebernstein L.P. boosted its holdings in shares of Mesa Laboratories by 52.9% in the second quarter. Alliancebernstein L.P. now owns 2,600 shares of the medical instruments supplier’s stock worth $373,000 after buying an additional 900 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Mesa Laboratories by 19.9% in the second quarter. Wells Fargo & Company MN now owns 3,326 shares of the medical instruments supplier’s stock worth $476,000 after buying an additional 553 shares during the last quarter. Finally, Bessemer Group Inc. boosted its holdings in shares of Mesa Laboratories by 716.7% in the second quarter. Bessemer Group Inc. now owns 4,900 shares of the medical instruments supplier’s stock worth $702,000 after buying an additional 4,300 shares during the last quarter. Hedge funds and other institutional investors own 67.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Martingale Asset Management L P Invests $1.16 Million in Mesa Laboratories, Inc. (MLAB)” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/09/24/martingale-asset-management-l-p-invests-1-16-million-in-mesa-laboratories-inc-mlab.html.

A number of research firms recently issued reports on MLAB. Zacks Investment Research downgraded shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, June 10th. BidaskClub downgraded shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Finally, TheStreet downgraded shares of Mesa Laboratories from a “b” rating to a “c+” rating in a report on Monday, July 31st.

Mesa Laboratories, Inc. (MLAB) opened at 142.90 on Friday. Mesa Laboratories, Inc. has a 12-month low of $109.14 and a 12-month high of $169.81. The stock has a market cap of $537.02 million, a P/E ratio of 51.37 and a beta of 0.47. The company has a 50 day moving average of $136.71 and a 200-day moving average of $138.57.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings data on Monday, July 31st. The medical instruments supplier reported $0.39 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.17). The firm had revenue of $22.67 million for the quarter, compared to analyst estimates of $22.90 million. Mesa Laboratories had a return on equity of 16.58% and a net margin of 11.31%. Equities analysts forecast that Mesa Laboratories, Inc. will post $2.74 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Thursday, August 31st were paid a dividend of $0.16 per share. The ex-dividend date of this dividend was Tuesday, August 29th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.45%. Mesa Laboratories’s payout ratio is 22.94%.

In other news, Director H Stuart Campbell sold 608 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $134.08, for a total transaction of $81,520.64. Following the sale, the director now owns 45,368 shares of the company’s stock, valued at approximately $6,082,941.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 8,610 shares of company stock worth $1,176,809 in the last ninety days. Corporate insiders own 17.00% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB).

Institutional Ownership by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.